| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Newfoundland Public Health Laboratory, Department of Health, Division of Community Medicine, Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland, A1B 3T2 Canada [S. R.]; Departments of Oncology and Epidemiology, McGill University, Montreal, Quebec H2W 1S6 Canada [E. L. F.]; Departments of Pathology and Obstetrics and Gynecology, McGill University and the Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, H3T 1E2 Canada [A. F.]
Our objective was to determine whether the addition of human papillomavirus (HPV) testing to screening cytology improves the detection of cervical cancer precursors. Women of ages 18–69 years underwent conventional Pap cytology and HPV DNA testing in a multicenter study in Newfoundland, Canada. Those with positive cytology and/or HPV and a random sample of those with dual negative results were referred for colposcopy. The study enrolled 2098 women. The relative sensitivity of HPV testing was significantly higher than cytology for all-grade squamous intraepithelial lesions [SILs; 73%; 95% confidence interval (CI), 62–82] and high grade SILs (HSILs; 90%; 95% CI, 74–97) but had lower relative specificity (62% for all-grade SILs and 51% for HSILs) than most cytological cutpoints. The rate of combined correct results for all-grade lesions was higher for HPV testing (68.8%) than for any cytological cutpoint (equivocal, 52.3%; LSILs, 51.6%; HSILs, 44.5%). The combination of HPV and an LSIL cutpoint had a negative predictive value of 68% (95% CI, 52–80) for all SILs and 100% (95% CI, 91–100) for HSILs, while referring for colposcopy only 12% of the women. We concluded that HPV testing in conjunction with cytology improved the screening efficacy of cytology alone and may allow for a more effective and safe primary screening program with increased screening intervals.
This article has been cited by other articles:
|
|
 |
|
  G. Ronco, P. Giorgi-Rossi, F. Carozzi, M. Confortini, P. D. Palma, A. Del Mistro, A. Gillio-Tos, D. Minucci, C. Naldoni, R. Rizzolo, et al. Results at Recruitment From a Randomized Controlled Trial Comparing Human Papillomavirus Testing Alone With Conventional Cytology as the Primary Cervical Cancer Screening Test J Natl Cancer Inst, April 2, 2008; 100(7): 492 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Schutzbank, C. Jarvis, N. Kahmann, K. Lopez, M. Weimer, and A. Yount Detection of High-Risk Papillomavirus DNA with Commercial Invader-Technology-Based Analyte-Specific Reagents following Automated Extraction of DNA from Cervical Brushings in ThinPrep Media J. Clin. Microbiol., December 1, 2007; 45(12): 4067 - 4069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Van de Velde, M. Brisson, and M.-C. Boily Modeling Human Papillomavirus Vaccine Effectiveness: Quantifying the Impact of Parameter Uncertainty Am. J. Epidemiol., April 1, 2007; 165(7): 762 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ronco, N. Segnan, P. Giorgi-Rossi, M. Zappa, G. P. Casadei, F. Carozzi, P. D. Palma, A. Del Mistro, S. Folicaldi, A. Gillio-Tos, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst, June 7, 2006; 98(11): 765 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Kulasingam, E. R. Myers, H. W. Lawson, K. J. McConnell, K. Kerlikowske, J. Melnikow, A. E. Washington, and G. F. Sawaya Cost-effectiveness of Extending Cervical Cancer Screening Intervals Among Women With Prior Normal Pap Tests Obstet. Gynecol., February 1, 2006; 107(2): 321 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Kim, T. C. Wright, and S. J. Goldie Cost-effectiveness of Human Papillomavirus DNA Testing in the United Kingdom, The Netherlands, France, and Italy J Natl Cancer Inst, June 15, 2005; 97(12): 888 - 895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G S Ogilvie, D M Patrick, M Schulzer, J W Sellors, M Petric, K Chambers, R White, and J M FitzGerald Diagnostic accuracy of self collected vaginal specimens for human papillomavirus compared to clinician collected human papillomavirus specimens: a meta-analysis Sex. Transm. Inf., June 1, 2005; 81(3): 207 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. G. Harris, R. D. Burk, J. M. Palefsky, L. S. Massad, J. Y. Bang, K. Anastos, H. Minkoff, C. B. Hall, M. C. Bacon, A. M. Levine, et al. Incidence of Cervical Squamous Intraepithelial Lesions Associated With HIV Serostatus, CD4 Cell Counts, and Human Papillomavirus Test Results JAMA, March 23, 2005; 293(12): 1471 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Anhang, A. Goodman, and S. J. Goldie HPV Communication: Review of Existing Research and Recommendations for Patient Education CA Cancer J Clin, September 1, 2004; 54(5): 248 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-M. Kulmala, S. Syrjanen, I. Shabalova, N. Petrovichev, V. Kozachenko, J. Podistov, O. Ivanchenko, S. Zakharenko, R. Nerovjna, L. Kljukina, et al. Human Papillomavirus Testing with the Hybrid Capture 2 Assay and PCR as Screening Tools J. Clin. Microbiol., June 1, 2004; 42(6): 2470 - 2475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Kahn Self-testing for human papillomavirus using a vaginal swab: placing prevention of cervical cancer in the patient's hands Ann. Onc., June 1, 2004; 15(6): 847 - 849. [Full Text] [PDF]
|
|
|
|
|
|
S. J. Goldie, J. J. Kim, and T. C. Wright Cost-Effectiveness of Human Papillomavirus DNA Testing for Cervical Cancer Screening in Women Aged 30 Years or More Obstet. Gynecol., April 1, 2004; 103(4): 619 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Harper, M. R. Longacre, W. W. Noll, D. R. Belloni, and B. F. Cole Factors Affecting the Detection Rate of Human Papillomavirus Ann. Fam. Med, November 1, 2003; 1(4): 221 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Sahebali, C E Depuydt, K Segers, A J Vereecken, E Van Marck, and J J Bogers Ki-67 immunocytochemistry in liquid based cervical cytology: useful as an adjunctive tool? J. Clin. Pathol., September 1, 2003; 56(9): 681 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Kulasingam and E. R. Myers Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs JAMA, August 13, 2003; 290(6): 781 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Franco Chapter 13: Primary Screening of Cervical Cancer With Human Papillomavirus Tests J Natl Cancer Inst Monographs, June 1, 2003; 2003(31): 89 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wacholder Chapter 18: Statistical Issues in the Design and Analysis of Studies of Human Papillomavirus and Cervical Neoplasia J Natl Cancer Inst Monographs, June 1, 2003; 2003(31): 125 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Saslow, C. D. Runowicz, D. Solomon, A.-B. Moscicki, R. A. Smith, H. J. Eyre, and C. Cohen American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer CA Cancer J Clin, November 1, 2002; 52(6): 342 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Kulasingam, J. P. Hughes, N. B. Kiviat, C. Mao, N. S. Weiss, J. M. Kuypers, and L. A. Koutsky Evaluation of Human Papillomavirus Testing in Primary Screening for Cervical Abnormalities: Comparison of Sensitivity, Specificity, and Frequency of Referral JAMA, October 9, 2002; 288(14): 1749 - 1757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Mandelblatt, W. F. Lawrence, L. Gaffikin, K. K. Limpahayom, P. Lumbiganon, S. Warakamin, J. King, B. Yi, P. Ringers, and P. D. Blumenthal Costs and Benefits of Different Strategies to Screen for Cervical Cancer in Less-Developed Countries J Natl Cancer Inst, October 2, 2002; 94(19): 1469 - 1483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Mandelblatt, W. F. Lawrence, S. M. Womack, D. Jacobson, B. Yi, Y.-t. Hwang, K. Gold, J. Barter, and K. Shah Benefits and Costs of Using HPV Testing to Screen for Cervical Cancer JAMA, May 8, 2002; 287(18): 2372 - 2381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F X Bosch, A Lorincz, N Munoz, C J L M Meijer, and K V Shah The causal relation between human papillomavirus and cervical cancer J. Clin. Pathol., April 1, 2002; 55(4): 244 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Wong and D Sutherland Canadian STI national goals and phase specific strategies Sex. Transm. Inf., April 1, 2002; 78(90001): i189 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Franco, E. Duarte-Franco, and A. Ferenczy Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection Can. Med. Assoc. J., April 1, 2001; 164(7): 1017 - 1025. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
